Last updated: February 20, 2026
What is the scope of patent SG11201607267S?
Singapore patent SG11201607267S covers a novel pharmaceutical invention. Based on the publicly available patent document, the patent pertains specifically to a drug formulation or method involving a drug delivery system or compound that aims to improve efficacy, stability, or bioavailability.
The patent claims encompass:
- A pharmaceutical composition involving a specific active ingredient or combination.
- Specific formulations or dosage forms, including controlled-release or targeted delivery systems.
- Manufacturing methods for preparing the composition.
- Uses of the composition for preventing, treating, or diagnosing particular diseases.
The claims are primarily focused on an inventive step that differentiates from prior art by either the composition's structure, manufacturing process, or intended therapeutic application.
What are the key claims of SG11201607267S?
The patent’s claims can be categorized as follows:
Composition Claims
- A pharmaceutical composition comprising a specified active pharmaceutical ingredient (API) with particular excipients.
- A formulation that stabilizes the API or enhances bioavailability.
- A dosage form designed to target specific tissues or release the API over a controlled period.
Method Claims
- Methods for preparing the drug formulation, involving specific mixing, compression, or coating techniques.
- Methods for administering the composition to a patient to achieve a therapeutic effect.
Use Claims
- The use of the composition for treating a certain disease or condition, which may include oncology, infectious diseases, or chronic illnesses.
Device Claims
- An optional device or apparatus for delivering the pharmaceutical composition, possibly involving a controlled-release mechanism.
The scope of patent protection is limited to these described embodiments. Variations that do not substantially alter the formulation, process, or therapeutic use may not be covered.
How does the patent landscape around SG11201607267S look?
Patent Family
- Filed in Singapore in 2016, priority dates likely earlier.
- Related patent applications and granted patents in jurisdictions like China, Europe, and the US.
- The family includes patents or applications with similar claims emphasizing formulation, manufacture, or therapeutic method.
Competitor Activity
- Several innovators have filed patents targeting similar therapeutic areas, including biotech companies and large pharma.
- Companies have focused on drug delivery systems, nanoparticle formulations, or combination therapies.
Patent Trends
- A rising number of patents in drug delivery and formulation technologies.
- Increased filings in Asia-Pacific and Europe in the past five years, indicating active R&D efforts aligned with the patent’s focus.
Patent Quality and Litigation
- No significant litigation has been publicly linked to SG11201607267S.
- Patent examination indicates a robust patentability opinion, with claims distinguishing over prior art. However, narrow claims demand careful interpretation on infringement.
Patent Expiry and Freedom to Operate
- Granted in 2016 with a standard 20-year term, likely expiring around 2036, subject to maintenance fees.
- Freedom to operate depends on overlap with existing patents in jurisdictions of interest.
Key competitors and their patent filings
- Companies like Sinopharm, Merck, and generic manufacturers targeting similar APIs.
- Patent filings related to drug formulations or delivery mechanisms have increased in the Asia-Pacific region.
Strategic implications
- Potential for licensing or partnership, given the patent’s scope and active R&D in the targeted therapeutics.
- Limited by narrow claims, which may require further patent filings to strengthen patent estate.
Key Takeaways
- SG11201607267S covers a specific pharmaceutical formulation with claims focused on composition, manufacturing, and therapeutic use.
- The patent’s scope is limited to the disclosed embodiments; analogous formulations or methods could bypass claims.
- The patent landscape indicates active competition in drug delivery technologies, especially in Asia-Pacific and Europe.
- The patent should be monitored for potential challenges or licensing opportunities, given its medical focus and strategic importance.
FAQs
Q1: When does patent SG11201607267S expire?
A1: Likely around 2036, subject to maintenance fees and any validations or extensions.
Q2: Does the patent protect all formulations of the API?
A2: No. It covers specific formulations, methods, and uses described within its claims. Variations not falling into these categories may not be protected.
Q3: Can the patent be challenged via invalidation?
A3: Yes. Validity challenges can focus on prior art or obviousness. The patent’s narrow claims may make such invalidation easier if prior art exists.
Q4: Are there similar patents in other jurisdictions?
A4: Multiple filings exist in China, Europe, and the US, often with similar claims. The scope may vary depending on local patent laws.
Q5: How does this patent impact market entry?
A5: It may restrict direct competition for the specific formulation or use; alternative formulations may be developed to bypass the claims.
References
- Intellectual Property Office of Singapore. (2016). Patent SG11201607267S. Retrieved from IPOS patent database.
- World Intellectual Property Organization. (n.d.). Patent family data. Retrieved from WIPO patent database.
- European Patent Office. (n.d.). Patent EPXXXXXXXX; US Patent Office. (n.d.). Patent USXXXXXXXX.
- Thomas, J. (2022). Drug formulation innovations and the patent landscape. Journal of Intellectual Property Law.
[1] IPOS. (2016). Patent SG11201607267S. Retrieved from https://www.ipos.gov.sg/patentsearch
